{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal COVI-MSC",
            "NStudiesAvail": 430108,
            "NStudiesFound": 6,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 6,
            "FieldList": [
                  "DesignTimePerspective",
                  "DesignWhoMasked",
                  "DetailedDescription",
                  "DispFirstPostDate",
                  "DispFirstPostDateType",
                  "DispFirstSubmitDate",
                  "DispFirstSubmitQCDate",
                  "EligibilityCriteria",
                  "EnrollmentCount",
                  "EnrollmentType",
                  "EventGroupDeathsNumAffected",
                  "EventGroupDeathsNumAtRisk",
                  "EventGroupDescription",
                  "EventGroupId",
                  "EventGroupOtherNumAffected",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [],
                        "DetailedDescription": [
                              "This is a Phase 1b multicenter study to assess the safety and efficacy of COVI-MSC in treating post COVID-19 \"long haulers\" with pulmonary compromise.\n\nCOVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nHas had prior laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen\nHas had a recent (within a week) negative SARS-CoV-2 test (an approved PCR or antigen test)\nHas had at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status\nWilling to follow contraception guidelines\n\nExclusion Criteria:\n\nClinically improving pulmonary status over the month prior to screening\nUndergone a previous stem cell infusion unrelated to this trial\nPregnant or breast feeding or planning for either during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection\nHistory of a splenectomy, lung transplant or lung lobectomy\nConcurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)"
                        ],
                        "EnrollmentCount": [
                              "0"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04909892"
                        ]
                  },
                  {
                        "Rank": 2,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a Phase 2 multicenter (United States and Mexico) study to assess the safety and preliminary efficacy of COVI-MSC in the setting of current standard of care in hospitalized subjects with RT-PCR confirmed SARS-CoV-2 (COVID-19) infection and acute respiratory stress (ARD) / acute respiratory distress syndrome (ARDS).\n\nSubjects will be randomized 1:1 COVI-MSC to placebo. COVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nLaboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen (can be documented from inpatient medical record)\nHospitalized with at least \"severe\" COVID-19-induced ARD or ARDS as defined per FDA Guidance; COVID-19: Developing Drugs and Biological Products for Treatment or Prevention\nRequires oxygen supplementation at Screening\nWilling to follow contraception guidelines\n\nExclusion Criteria:\n\nCurrent standard of care treatments for COVID-19 appear to be working and the subject is clinically improving\nHas severe ARDS with a PaO2/FiO2 (PF ratio) \u2264 100 mmHg or SpO2/FiO2 ratio < 150 mmHg with PEEP \u2265 5cm H2O\nA previous stem cell infusion unrelated to this trial\nPregnant or breast feeding or planning for either during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with COVID-19)\nHistory of a splenectomy, lung transplant or lung lobectomy\nConcurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)\nExpected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days\nHas an existing \"Do Not Intubate\" order\nHas undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing (eg, obstructive sleep apnea)\nHas any significant medical condition, laboratory abnormality or psychiatric illness that in the investigator's opinion would interfere or prevent the subject from safely participating in the study"
                        ],
                        "EnrollmentCount": [
                              "60"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04905836"
                        ]
                  },
                  {
                        "Rank": 3,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a Phase 2, randomized controlled, multicenter study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for subjects hospitalized subjects with acute respiratory distress syndrome not related to COVID-19 infection.\n\nSubjects will be randomized 2:1 to receive COVI-MSC or placebo. COVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nNegative for SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen\nHospitalized with non-COVID-19-induced ARDS (any severity) with a PaO2/FiO2 (PF ratio) \u2264 300\nRequires oxygen supplementation at Screening\nWilling to follow contraception guidelines\n\nExclusion Criteria:\n\nCurrent standard of care treatments for ARDS appear to be working and the subject is clinically improving\nA previous stem cell infusion unrelated to this trial\nPregnant or breast feeding or planning for either during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection\nHistory of a splenectomy, lung transplant or lung lobectomy\nConcurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)\nExpected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days"
                        ],
                        "EnrollmentCount": [
                              "0"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04909879"
                        ]
                  },
                  {
                        "Rank": 4,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a Phase 2a randomized, placebo-controlled multicenter study designed to investigate the efficacy, safety and tolerability of COVI-MSC in treating post COVID-19 \"long haul\" pulmonary compromise.\n\nCOVI-MSC will be administered intravenously on Day 0, Day 2, and Day 4."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nHas had prior laboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen\nHas had a recent (within a week) negative SARS-CoV-2 test (an approved PCR or antigen test)\nHas had at least moderate or severe post-COVID-19 pulmonary symptoms for at least 3 months which have resulted in reduced physical functioning compared to pre-COVID-19 status\nWilling to follow contraception guidelines\n\nExclusion Criteria:\n\nClinically improving pulmonary status over the month prior to screening\nUndergone a previous stem cell infusion unrelated to this trial\nPregnant or breast feeding or planning for either during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection\nAny significant medical condition, laboratory value or other illness that in the investigator's opinion would interfere or prevent safe participation in the study\nHistory of a splenectomy, lung transplant or lung lobectomy\nConcurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable)"
                        ],
                        "EnrollmentCount": [
                              "60"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04992247"
                        ]
                  },
                  {
                        "Rank": 5,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Investigator"
                        ],
                        "DetailedDescription": [],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nProvides informed consent\nHas laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen\n3. Is hospitalized with COVID-19-induced ARD or ARDS (any severity) with a PaO2/FiO2 \u2264300. The PaO2/FiO2 may be estimated from pulse oximetry or determined by arterial blood gas\nRequires oxygen supplementation at screening\nIs willing to follow contraception requirements\n\nExclusion Criteria:\n\nCurrent standard of care treatments for COVID-19 appear to be working and the subject is clinically improving\nA previous MSC infusion unrelated to this trial\n\nHave any of the following medical conditions:\n\nCardio-pulmonary resuscitation within 14 days of randomization\nUncontrolled or untreated symptomatic arrhythmias. Exception: Subjects with controlled, asymptomatic atrial fibrillation during screening may enroll\nMyocardial infarction within the last 6 weeks\nCongestive heart failure (NYHA Grade 3 or 4)\nPulmonary hypertension (WHO Class III/IV)\nCurrently receiving extracorporeal life support or membrane oxygenation (ECLS/ECMO)\nAlanine aminotransferase (ALT) \u2265 5x upper limit of normal (ULN)\nRelevant renal impairment (eGFR < 50 mL/min)\nAny significant medical condition, laboratory abnormality or psychiatric illness that in the investigator's opinion would interfere or prevent the subject from safely participating in the study\nPregnant or breast feeding or planning for either during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection (aside from infection with COVID-19)\nHistory of a splenectomy, lung transplant or lung lobectomy;\nConcurrent participation in another clinical trial involving therapeutic interventions (observational study participation is acceptable).\nExpected survival or time to withdrawal of life-sustaining treatments expected to be < 7 days.\nDo Not Intubate order;\nHome mechanical ventilation (noninvasive ventilation or via tracheotomy) except for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing"
                        ],
                        "EnrollmentCount": [
                              "0"
                        ],
                        "EnrollmentType": [
                              "Actual"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04728698"
                        ]
                  },
                  {
                        "Rank": 6,
                        "DesignTimePerspective": [],
                        "DesignWhoMasked": [
                              "Participant",
                              "Care Provider",
                              "Investigator",
                              "Outcomes Assessor"
                        ],
                        "DetailedDescription": [
                              "This is a Phase 2 randomized controlled study to assess the safety and efficacy of COVI-MSC in the setting of current standard of care treatments for COVID-19 infection in hospitalized subjects with acute respiratory distress syndrome.\n\nCOVI-MSC or placebo will be administered intravenously on Day 0, Day 2, and Day 4.\n\nAcceptable standard of care treatments for COVID-19 include all approved or emergency use authorized treatments for COVID-19, even if used off-label."
                        ],
                        "DispFirstPostDate": [],
                        "DispFirstPostDateType": [],
                        "DispFirstSubmitDate": [],
                        "DispFirstSubmitQCDate": [],
                        "EligibilityCriteria": [
                              "Inclusion Criteria:\n\nLaboratory-confirmed SARS-CoV-2 infection as determined by an approved polymerase chain reaction (PCR) or an approved antigen test of any specimen\nHospitalized with COVID-19-induced ARD or ARDS (any severity) with a PaO2/FiO2 (PF ratio) \u2264 300\nRequires oxygen supplementation at Screening\nWilling to follow contraception guidelines\n\nExclusion Criteria:\n\nCurrent standard of care treatments for COVID-19 appear to be working and the subject is clinically improving\nA previous stem cell infusion unrelated to this trial\nCertain medical conditions that pose a safety risk to the subject\nPregnant or breast feeding or planning to during the study\nSuspected uncontrolled active bacterial, fungal, viral, or other infection\nHistory of splenectomy, lung transplant, or lung lobectomy\nConcurrent participation in another clinical trial involving therapeutic interventions\nExpected survival or time to withdrawal of life-sustaining treatments expected to be <7 days\nHas an existing \"Do Not Intubate\" order\nHas undergone home mechanical ventilation (noninvasive ventilation or via tracheotomy) expect for continuous positive airway pressure or bi-level positive airway pressure (CPAP/BIPAP) used solely for sleep-disordered breathing"
                        ],
                        "EnrollmentCount": [
                              "100"
                        ],
                        "EnrollmentType": [
                              "Anticipated"
                        ],
                        "EventGroupDeathsNumAffected": [],
                        "EventGroupDeathsNumAtRisk": [],
                        "EventGroupDescription": [],
                        "EventGroupId": [],
                        "EventGroupOtherNumAffected": [],
                        "NCTId": [
                              "NCT04903327"
                        ]
                  }
            ]
      }
}